mRNA pioneer BioNTech announced recently that it is developing an mRNA-based vaccine to attempt to eradicate malaria. Its efforts are
Prime Medicine Emerges with $315 Million to Develop Next Generation Gene Editing Platform
On July 13, 2021, Prime Medicine, a Massachusetts biotech company developing next generation gene editing technology, emerged from stealth mode
Continue Reading Prime Medicine Emerges with $315 Million to Develop Next Generation Gene Editing Platform
Domain Name “Trolls”: The Trademark Trial and Appeal Board May Have Offered A Way Out
In today’s world, e-commerce and online visibility are sine qua non for success. Businesses are willing to invest considerable sums
Continue Reading Domain Name “Trolls”: The Trademark Trial and Appeal Board May Have Offered A Way Out
Ceribell Announces Completion of $53 Million Series C Financing for Portable EEG that can Diagnose Seizures in Minutes
On April 29, 2021, Mountain View, California-based startup Ceribell, Inc. announced the completion of a $53 million Series C financing,
Continue Reading Ceribell Announces Completion of $53 Million Series C Financing for Portable EEG that can Diagnose Seizures in Minutes
The mRNA Patent and Competitive Landscape: Pioneers, Litigation Outlook and Big Pharma’s Next Moves (Part III)
In Part I of this series providing a summary of the mRNA IP and competitive landscape through one year of
Continue Reading The mRNA Patent and Competitive Landscape: Pioneers, Litigation Outlook and Big Pharma’s Next Moves (Part III)
Capsida Biotherapeutics Debuts with $140 Million of Capital for its AAV Gene Therapies
Capsida Biotherapeutics Inc.—a Thousand Oaks, CA-based emerging biotechnology company—recently emerged from stealth mode with $ 140 million in start-up capital
Continue Reading Capsida Biotherapeutics Debuts with $140 Million of Capital for its AAV Gene Therapies
The mRNA Patent and Competitive Landscape: Translate BIO; Arcturus; eTheRNA and Other Startups; and LNP Technology (Part II)
In Part I of this three-part series, we focused on three mRNA technology market players: BioNTech, Moderna and CureVac.
Continue Reading The mRNA Patent and Competitive Landscape: Translate BIO; Arcturus; eTheRNA and Other Startups; and LNP Technology (Part II)
The mRNA Patent and Competitive Landscape Through One Year of the COVID-19 Pandemic–Part I
Shortly after we posted about Moderna, Inc.’s October 2020 pledge not to enforce its COVID-19-related patents during the pandemic, the
Continue Reading The mRNA Patent and Competitive Landscape Through One Year of the COVID-19 Pandemic–Part I
Bigfoot Biomedical® Secures up to $57 Million in Financing from Madryn Asset Management
Bigfoot Biomedical®, a Milpitas, CA emerging company, recently announced that it has secured new financing of up to $57
Continue Reading Bigfoot Biomedical® Secures up to $57 Million in Financing from Madryn Asset Management
Dana-Farber Launches New Fund to Support Oncology Startups
2021 started off well for Dana-Farber Cancer Institute, with the launch of its new venture fund, Binney Street Capital,
Continue Reading Dana-Farber Launches New Fund to Support Oncology Startups